查詢結果分析
來源資料
相關文獻
- An Add-On Study of Selegiline to Madopar in the Treatment of Parkinsonian Patients with Dose-Related Fluctuations: Comparison between Jumexal and Parkryl
- 巴金森氏病患之吞嚥障礙及電視螢光錄影檢查
- 抽菸與巴金森氏病
- 憂鬱症與巴金森氏病
- 神經學之最新發展(4):巴金森氏病(Parkinson's Disease)之研究發展--從MPTP到組織植入大腦的研究
- Image of Parkinsonian Monkey Using [fee6]Tc-TRODAT-1: A Preliminary Report
- 巴金森氏病的胃腸功能障礙
- 巴金森氏病的認識
- 巴金森氏病之基因易感性
- Monitoring of the Levodopa Concentration-Response Relationship in Parkinson's Disease
頁籤選單縮合
題 名 | An Add-On Study of Selegiline to Madopar in the Treatment of Parkinsonian Patients with Dose-Related Fluctuations: Comparison between Jumexal and Parkryl=使用Selegiline附加於Madopar治療併發藥效波動症狀之巴金森氏病患者試驗: 比較Jumexal與Parkryl之作用 |
---|---|
作 者 | 單定一; 葉士英; | 書刊名 | 中華醫學雜誌 |
卷 期 | 58:4 1996.10[民85.10] |
頁 次 | 頁264-268 |
分類號 | 415.83 |
關鍵詞 | 藥效波動; 巴金森氏病; Motor fluctuation; Parkinson's disease; Selegiline; |
語 文 | 英文(English) |
中文摘要 | 背景 為改善巴金森氏病患者藥效波動之症狀,我們評估了一種選擇 性B型單胺氧化酵素抑制劑selegiline之療效。 方法 我們篩選了20位患者加入這一個短期、單盲及交替的臨床試驗。每1 位患者先接受一種廠牌的selegiline - Parkryl(美時)每天10毫克,加入原有的 Madopar治療中。在治療六週後,患者接受四週安慰劑治療,再接受另一種廠 牌的selegiline - Jumexal (Labatec)治療六週。 結果 有5位患者因為出現異動症、幻覺及燥動不安而放棄試驗。在完成此試 驗之15位患者中,Parkryl與Jumexal的治療都使有效期動作指數呈現輕微的進 步(p < 0.0l及p < 0.05)。Parkryl使失效期所佔的百分比從37.8%降為20.7% (p < 0.01),Jumexal則使失效期所佔的百分比降為21.0% (p < 0.01)。 結論 Selegiline作為Madopar的輔助療法,對於併發藥效波動症狀之巴金森氏 病患者有效期時間的延長,有中度的療效。Jumexal之療效似乎並不比Parkryl 更強。 |
英文摘要 | Background. To improve dose-related fluctuations in patients with Parkinson's disease, the efficacy of selegiline, a selective inhibitor of monoamine oxidase B, was determined. Methods. Twenty parkinsonian patients were selected for a short-term, single- blind, cross-over trial. Each patient received one of the two brands of selegiline, Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar. After a 6-week treatment period and a 4-week wash-out period, the treatment was switched to the other brand of selegiline, Jumexal (Labatec), for another 6 weeks. Results. Five patients dropped out of the study because of the development of intolerable dyskinesia, hallucination or agitation. The 15 patients that completed the study made a mild improvement in the total motor scores of the on-period during both treatments of Parkryl (p < 0.01) and of Jumexal (p < 0.05). The recorded daily off-time decreased from 37.8% to 20.7% in the Parkryl group (p < 0.01), and to 21.0% in the Jumexal group (p < 0.01). Conclusions. Selegiline, as an adjunct therapy to Madopar, has a moderate effect in prolonging the duration of on-time in parkinsonian patients with dose-related fluctuations. Jumexal seemed to produce no greater effect than Parkryl. |
本系統中英文摘要資訊取自各篇刊載內容。